Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Heinz Zeichhardt

Showing results (1-10 of 57) with videos related to

Pageof 6
Sort By:
The Lancet. Microbe|February 6, 2023
Ignoring SARS-CoV-2 testing performance during COVID-19Christoph Buchta, Heinz Zeichhardt, Andrea Griesmacher, et al.
The Lancet. Microbe|November 17, 2023
Do not blindly trust negative diagnostic test results!Christoph Buchta, Heinz Zeichhardt, Andreas Osterman, et al.
Antiviral Research|November 7, 2016
Soluble coxsackie- and adenovirus receptor (sCAR-Fc); a highly efficient compound against laboratory and clinical strains of coxsackie-B-virusSandra Pinkert, Babette Dieringer, Sabine Diedrich, et al.
International Journal of Medical Microbiology : IJMM|September 7, 2015
Does proficiency testing improve the quality of hantavirus serodiagnostics? Experiences with INSTAND EQA schemesJörg Hofmann, Hans-Peter Grunert, Oliver Donoso-Mantke, et al.
Plos One|February 6, 2013
Spiegelzymes: sequence specific hydrolysis of L-RNA with mirror image hammerhead ribozymes and DNAzymesEliza Wyszko, Maciej Szymański, Heinz Zeichhardt, et al.
Oligonucleotides|July 24, 2010
Rapid construction of adeno-associated virus vectors expressing multiple short hairpin RNAs with high antiviral activity against echovirus 30Diana Rothe, Gisela Wajant, Hans-Peter Grunert, et al.
FEBS Letters|December 17, 2009
Application of small interfering RNAs modified by unlocked nucleic acid (UNA) to inhibit the heart-pathogenic coxsackievirus B3Denise Werk, Jesper Wengel, Suzy L Wengel, et al.
Journal of Molecular Biology|January 27, 2005
Maintaining inhibition: siRNA double expression vectors against coxsackieviral RNAsSteffen Schubert, Hans-Peter Grunert, Heinz Zeichhardt, et al.
Journal of Infection and Public Health|January 17, 2022
Evaluation of the diagnostic capacities for emerging arboviral diseases in the international network MediLabSecure from 2014 to 2018 - Importance of external quality assessmentsGuillain Mikaty, Séverine Matheus, Oliver Donoso Mantke, et al.
FEBS Letters|August 12, 2008
Design of LNA-modified siRNAs against the highly structured 5' UTR of coxsackievirus B3Mariola Dutkiewicz, Hans-Peter Grunert, Heinz Zeichhardt, et al.
Pageof 6

Showing results (1-10 of 57) with videos related to

Sort By:
Pageof 6
The Lancet. Microbe|February 6, 2023
Ignoring SARS-CoV-2 testing performance during COVID-19Christoph Buchta, Heinz Zeichhardt, Andrea Griesmacher, et al.
The Lancet. Microbe|November 17, 2023
Do not blindly trust negative diagnostic test results!Christoph Buchta, Heinz Zeichhardt, Andreas Osterman, et al.
Antiviral Research|November 7, 2016
Soluble coxsackie- and adenovirus receptor (sCAR-Fc); a highly efficient compound against laboratory and clinical strains of coxsackie-B-virusSandra Pinkert, Babette Dieringer, Sabine Diedrich, et al.
International Journal of Medical Microbiology : IJMM|September 7, 2015
Does proficiency testing improve the quality of hantavirus serodiagnostics? Experiences with INSTAND EQA schemesJörg Hofmann, Hans-Peter Grunert, Oliver Donoso-Mantke, et al.
Plos One|February 6, 2013
Spiegelzymes: sequence specific hydrolysis of L-RNA with mirror image hammerhead ribozymes and DNAzymesEliza Wyszko, Maciej Szymański, Heinz Zeichhardt, et al.
Oligonucleotides|July 24, 2010
Rapid construction of adeno-associated virus vectors expressing multiple short hairpin RNAs with high antiviral activity against echovirus 30Diana Rothe, Gisela Wajant, Hans-Peter Grunert, et al.
FEBS Letters|December 17, 2009
Application of small interfering RNAs modified by unlocked nucleic acid (UNA) to inhibit the heart-pathogenic coxsackievirus B3Denise Werk, Jesper Wengel, Suzy L Wengel, et al.
Journal of Molecular Biology|January 27, 2005
Maintaining inhibition: siRNA double expression vectors against coxsackieviral RNAsSteffen Schubert, Hans-Peter Grunert, Heinz Zeichhardt, et al.
Journal of Infection and Public Health|January 17, 2022
Evaluation of the diagnostic capacities for emerging arboviral diseases in the international network MediLabSecure from 2014 to 2018 - Importance of external quality assessmentsGuillain Mikaty, Séverine Matheus, Oliver Donoso Mantke, et al.
FEBS Letters|August 12, 2008
Design of LNA-modified siRNAs against the highly structured 5' UTR of coxsackievirus B3Mariola Dutkiewicz, Hans-Peter Grunert, Heinz Zeichhardt, et al.
Pageof 6